secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-267758
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Therapeutics appoints Esther Rajavelu as CFO and CBO effective Nov 6
--------------------------------------------------------------------------

- Esther Rajavelu appointed CFO and Chief Business Officer; assumes principal financial officer role after Q3 10-Q filing.
- Annual base salary of $475,000; sign-on bonus of $50,000; target annual cash bonus of 40% of base salary.
- Grant of 300,000 RSUs under inducement plan, vesting in equal annual installments over four years starting Nov 6, 2024.
- Interim CFO Stephen DiPalma continues until Q3 10-Q filed; may consult post-transition.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/0001193125-23-267758-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312523267758/d506257d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-267758

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer